1 / 32

Pediatric Lymphomas

Pediatric Lymphomas. Resident Education Lecture Series. Cervical adenopathy. Size >1-2 cm Increasing size over 2-4 weeks Matted or fixed Supraclavicular LN. Fevers >38.5 for 2-4 weeks Constitutional symptoms HSM. Concerns in enlarged LN. When to biopsy. Supraclavicular node

rowa
Download Presentation

Pediatric Lymphomas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatric Lymphomas Resident Education Lecture Series

  2. Cervical adenopathy

  3. Size >1-2 cm Increasing size over 2-4 weeks Matted or fixed Supraclavicular LN Fevers >38.5 for 2-4 weeks Constitutional symptoms HSM Concerns in enlarged LN

  4. When to biopsy • Supraclavicular node • Increasing size over 2-4 weeks • Constitutional symptoms • Asymptomatic enlarged node-not decreasing in size over 6 weeks or not normal after 8-12 weeks

  5. Laboratory -CBC with smear -Chem profile LHD, uric acid Disease specific -ESR, IL2R for HD -LP if head/neck NHL -BMA/Bx for all NHL, only IIB or higher HD Radiology -CXR (PA & Lat) -CT scans neck, chest, abdomen -Gallium, bone scan -PET scan Staging Evaluation

  6. Lymphoma Staging • Murphy  Ann Arbor • I: tumor at one site (nodal or extranodal -- “E”) • II: two or more sites; same side of body (or resectable GI primary) • III: both sides of body but not IV (& unresec. GI & mediastinal for NHL) • IV: CNS or marrow involvement (Murphy); lung, liver, marrow, or bone for Ann Arbor (< 25% marrow) • “B” sxs are defined for HD, as is “bulky disease” • Head and neck (possibility of CNS involvement) is a further consideration for NHL • PET or gallium

  7. LYMPHOMA HODGKINS NON-HODGKINS (40%) (60%) BURKITT’S LYMPHOMA LARGE CELL LYMPHOMA LYMPHOBLASTIC LYMPHOMA (<15%) (30-40%) (40-50%) IMMUNOBLASTIC ANAPLASTIC (50%) (50%)

  8. Non-Hodgkin’s Lymphoma • Malignant solid tumor of immune system • Undifferentiated lymphoid cells • Spread: aggressive, diffuse, unpredictable • Lymphoid tissue; BM and CNS infiltration • High growth fraction and doubling time • Dx and Rx ASAP • Rapid CTX response; tumor lysis concern

  9. Incidence/Etiology - NHL • 6% childhood cancer 60% of childhood lymphomas • Peak age of 5-15; M:F ratio of 2.5:1 • Increased with • SCIDS, HIV, EBV • post t-cell depleted BMT • post solid organ transplant • Geographic, viral, genetic & immunologic factors

  10. Types of NHL Lymphoblastic (30-35%) • 90 % immature T cells (very similar to T-ALL) • remainder pre-B phenotype (as in ALL) • 50-70% anterior mediastinum • neck, supraclavicular, axillary adenopathy • Classic: older child with intussusception

  11. Small non-cleaved cell (40-50%) --Mature B-cell phenotype --Burkitt's and non-Burkitt's --90% abdomen --Ascites and intusussception --Endemic in Africa (Burkitt's), with EBV 97%

  12. Burkitt Facts • 100 new cases/year in US, 2-3:1 male:female; mean age 11 years (in non-endemic form) • small, noncleaved cell; mature B phenotype; intraabdominal (sporadic) or jaw (endemic) most common primary site • 90% have t(8;14) • (8 ~ c-myc; 14 ~ heavy chains) • others are 8;2 or 8;22 • (2, 22 ~ light chains) • Extremely rapidly-growing; tumor lysis issues

  13. Burkitt Prognosis Adult Data: Stage: EFS OS I-II 91% 78% IV 25% 25% but in patients < 40 yo 70% 60% Pediatric Data: Localized > 90% Disseminated (but not B- ALL) 80-90% on newer protocols

  14. Large-cell lymphoma (15-20%) • Anaplastic (Ki-1) lymphoma – ALK fusion protein • Diffuse Large B-cell lymphoma (DLBCL) • frequent Mediastinal involvement • More like Hodgkin lymphoma than other NHLs • “Peripheral T-cell” lymphoma • Often involves skin, CNS, lymph nodes, lung, testes, muscles, and GI tract

  15. “low grade” lymphomas – rare in children • Follicular • marginal zone/MALT • primary CNS (often seen with HIV infection) • peripheral cutaneous (mycosis fungoides)

  16. Clinical Presentations • Abdomen: (35%): pain, distention, jaundice, GI problems, mass • Head/neck (13%): lymphadenopathy, jaw swelling, single enlarged tonsil, nasal obstruction, rhinorrhea, cranial nerve palsies • Mediastinum (26%): SVC syndrome • CNS (rare): HA, V, irritability, papilledema +Fever, malaise, night sweats, wt. loss,

  17. Prognosis affected by… • Incomplete remission in first 2 mos. Rx • Large tumor burden (LDH >1000) • Stages III and IV: CNS or BM involvement • Delay in treatment • Relapse **More favorable: Stage I or II, head/neck, peripheral nodes, GI tract

  18. NHL Treatment • Surgery for diagnostic bx or second look • Radiation Therapy: emergency airway obstruction or CNS complication – may be used for local control of residual mass • Chemotherapy: Combination chemo is usual, with overall cure rates 60-80+%; high risk of tumor lysis and hyperuricemia • Relapse: Re-induction, followed by BMT

  19. Hodgkin’s Disease • Immune system malignancy, involving B or T lymphocytes • Reed-Sternberg cells • Spread: slow, predictable, with extension to contiguous lymph nodes • Infiltration to non-lymphoid organs is rare

  20. Hodgkin’s disease with Reed Sternberg cell often CD20+

  21. Incidence and Etiology • Hodgkin’s 5% of childhood cancers • Bimodal peaks, at 15-35 and >50; rare < 5 • M:F ratio of 3:1; variation r/t geography and SES, and type • Increased in immunologic disorders, HIV, EBV

  22. Types of Hodgkin’s Lymphoma • Nodular sclerosing (NS), 40-60%, lower cervical, supraclavicular, mediastinal nodes • Mixed cellularity (MC), 15-30%; advanced disease with extranodal involvement • Lymphocyte predominance (LP), 5-15%, presents as localized disease • Lymphocyte depletion (LD) (<5%); widespread disease

  23. Clinical Presentation • Painless lymph node swelling (90%) that persists despite antibiotic therapy • Palpable non-tender, firm, mobile, rubbery nodes; Mediastinal adenopathy (60%); SVC • Bulky: when mass is > 1/3 thorax diameter • B symptoms: Fever of >38C for 3 days, drenching night sweats, 10% weight loss

  24. Mediastinal masses • Risk for anesthesia (esp. if tracheal compression > 50% by CT) • Least invasive diagnostic procedure therefore indicated (incl. thoracentesis) • Emergent steroids or RT generally acceptable prior to biopsy • HD and DLBCL tend to have areas of necrosis and therefore look more “bumpy” than T-ALL

  25. Prognosis FAVORABLE: <10, F, favorable subtypes (LP and NS) and Stage I non-bulky disease UNFAVORABLE: Persistently elevated ESR; LD histopathology; bulky disease--largest dimension >10cm; B symptoms;

  26. Treatment and Prognosis • Dependent on age, stage, and tumor burden • RT alone, CTX alone • RT: varies from involved field for localized disease to extended field to total nodal irradiation, inverted Y plus mantle • most often multimodal therapy, with low-dose involved field RT and multi-agent CTX • Combined modality 70-90% LT cure

  27. Hodgkin Px and Rx • Splenectomy generally no longer used • Exact type and ratio of combined modality therapy changes… due to differences in success rates for salvage therapy and concerns for late effects of therapy • Second malignancy risks • Sterility risks

  28. From ABP Certifying Exam Content Outline • Know how to evaluate a child with an acute cervical lymphadenopathy • Know the differential diagnosis of neck masses: • lymphoma, • cystic hygroma, • thyroglossal duct cyst • branchial cleft abnormalities

  29. From ABP Certifying Exam Content Outline, continued • Recognize the need for evaluation of supraclavicular lymph node enlargement • Identify the chest x-ray as an important part of the initial evaluation of the patient with an unexplained lymphadenopathy • Know that overwhelming sepsis is a serious complication in patients with Hodgkin disease who have undergone splenectomy, • and know that such patients should be evaluated thoroughly if fever develops

  30. Credits • Meghen Browning MDAnne Warwick MD MPH

More Related